Look after the kidneys and you look after the heart

Beverley Bostock shares a practical approach to CKD in primary care, from checking ACR and eGFR to reducing cardiovascular risk, treatment and the questions she is asked most.
My approach in life is to keep things simple. So here is the one message I want you to take from this article. Chronic kidney disease (CKD) is a cardiovascular risk factor. A person with CKD is more likely to die of a cardiovascular event than to reach dialysis 1. Yet tell a patient they have kidney disease and they think of transplants. Nobody thinks of a heart attack. That is the gap we need to close.
The heart and the kidneys are one coin with different sides, not different coins. If you have CKD you are more likely to have a cardiovascular event. If you have cardiovascular disease, or heart failure, you are more likely to have CKD 2. Look after one and you look after the other.
When kidneys come under pressure, the first thing they let slip is protein. That is why the urine albumin to creatinine ratio (ACR) matters so much. A normal eGFR can be fake, propped up by hyperfiltration while the kidneys quietly exhaust themselves. A raised ACR is their cry for help. It is also an independent risk factor for cardiovascular events and heart failure 3.
We are nowhere near testing the people we should, and ACR is the biggest gap. My phrase of the year is "any pee will do". Take whatever sample the patient can give. Chase the early morning one on repeat. And please do not wait for the eGFR to drop below 60 before you check an ACR. NICE asks for both tests in everyone at risk, and very often the ACR is the first red flag 4.
The diagnosis itself is simple 4:
- eGFR below 60, or ACR of 3 mg/mmol or more
- Either result is enough. You do not need both
- Sustained for at least three months
- A first eGFR below 60 needs a repeat within two weeks to rule out acute kidney injury
I saw a patient whose eGFR fell from the 70s to 58, then the 40s, then the teens. It was interstitial nephritis. Don't miss that early repeat.
Two patients show why both numbers matter:
- Sara, 59: eGFR 49, ACR 2.5. That is G3a A1, moderately increased risk on the KDIGO heat map 2.
- Anthony, 67, type 2 diabetes: eGFR 58, ACR 3.4. That is G3a A2, high risk 2.
The better eGFR carries the worse prognosis. If I haven't got an ACR, I honestly can't tell a patient what their kidney health is like.
Treatment starts with lifestyle. Smoking cessation. Healthy eating. Alcohol within limits 4. A teaspoon of salt a day at most 5. Immunisations, which I frame as cardiovascular protection rather than a way to avoid a week in bed 6. Then come the medicines I describe to patients as pieces of armour.
My alphabet of CKD is the treatment plan in six letters:
- A for ACR
- B for BP, with an ACE inhibitor or ARB titrated to the maximum tolerated dose 4
- C for cholesterol, lowered with a statin 7
- D for an SGLT2 inhibitor 4
- E for eGFR monitoring 4
- F for a non-steroidal MRA in diabetic kidney disease 8
On statins, NICE is clear. People with CKD do not need a risk score. Their risk is already high enough 7. I once brought 16 statin-naive patients with CKD into one room for an hour and explained why. Fifteen left with a prescription.
Sick day rules deserve their own reminder, SADMAN: SGLT2 inhibitors, ACE inhibitors, diuretics, metformin, ARBs and NSAIDs. Pause while unwell, restart when better 9. For referral, run the kidney failure risk equation. A 5% risk in five years means refer 4. And to finish, ROAR: recognise it, optimise treatment, address CVD risk, refer.
The questions I get asked most
These came up at my recent Medicine Central webinar, and they come up in practice every week.
- Do you start an ACE inhibitor or ARB even when BP and ACR are normal? Yes, for the cardiorenal protection. Titrate gradually, check sitting and standing blood pressure, and factor in frailty.
- KDIGO only recommends statins in CKD over 40. What about younger patients? Absolutely, no question. Look for the cause of CKD in a young person, but NICE recommends a statin for CKD regardless of age 7.
- How much eGFR drop after starting a RAAS inhibitor should worry me? Expect a small dip, like a Nike tick, then recovery. NICE sets the threshold for action at a 25% fall in eGFR or a 30% rise in creatinine 4. Look for other causes before stopping, and if you must step back, some RAAS inhibition is better than none.
- Patients in their late 80s and 90s with ACR-based CKD: treat or leave alone? Play for today or plan for tomorrow. Ask the patient. Evidence is thin at that age, so weigh falls risk against benefit and respect their choice.
- Normal ACR, no other conditions, eGFR under 45: can I start an SGLT2 inhibitor? Yes. EMPA-KIDNEY showed benefit across albuminuria levels, and recruited down to an eGFR of 20 10. I would not initiate below that.
What does this mean in primary care?
None of this is extra work. These patients are already in front of us for their long-term condition reviews. 5 steps include:
- Get the ACR on everyone who should have one.
- Diagnose on either number, not just eGFR.
- When you code CKD, think cardiovascular risk in the same breath.
- Check the KFRE before you refer.
- Tell patients why: not only to save their kidneys, but to protect their heart.
Beverley's Medicine Central webinar on CKD in primary care is available on demand with 1 CPD point.
References
- Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663. https://doi.org/10.1001/archinte.164.6.659
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
- Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–525. https://doi.org/10.1016/S2213-8587(15)00040-6
- National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. NICE guideline NG203. August 2021, last updated November 2021. https://www.nice.org.uk/guidance/ng203 (accessed November 2026).
- National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline NG136. August 2019, last updated November 2023. https://www.nice.org.uk/guidance/ng136 (accessed November 2026).
- Behrouzi B, Bhatt DL, Cannon CP, et al. Association of influenza vaccination with cardiovascular risk: a meta-analysis. JAMA Netw Open. 2022;5(4):e228873. https://doi.org/10.1001/jamanetworkopen.2022.8873
- National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG238. December 2023. https://www.nice.org.uk/guidance/ng238 (accessed November 2026).
- National Institute for Health and Care Excellence. Finerenone for treating chronic kidney disease in type 2 diabetes. Technology appraisal TA877. March 2023. https://www.nice.org.uk/guidance/ta877 (accessed November 2026).
- Think Kidneys, NHS England. Sick day guidance in patients at risk of acute kidney injury. 2018. https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2018/01/Think-Kidneys-Sick-Day-Guidance-2018.pdf (accessed November 2026).
- The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127. https://doi.org/10.1056/NEJMoa2204233
Intended for UK healthcare professionals only. This article reflects the clinical opinion of the author and does not constitute prescribing advice.
